TriNetX licenses access to data on about 300 million patients to Regeneron for drug discovery
TriNetX licenses Regeneron access to de-identified health data on about 300 million people, with the exclusive opportunity to connect Regeneron's own genomic and proteomic cohorts to TriNetX's phenotypic network. Regeneron will also invest up to $200 million in TriNetX.
Where the rake sits
TriNetX keeps a licence fee for access to its harmonised network. The drug-discovery value comes from work Regeneron does: joining its own Genetics Center genomic and proteomic cohorts to TriNetX's phenotypic records. So TriNetX has no downstream rake, owned or on loan. Regeneron's investment of up to $200 million is equity in TriNetX, not part of the rake. The live question is under-capture: whether the fee priced the exclusivity, which stops TriNetX selling the same genomic link to any other drugmaker.
What happened
- Announced 2 April 2026 by TriNetX and Regeneron Pharmaceuticals.
- Licensed access to de-identified health data on about 300 million people, 170 million of them in the US, from TriNetX's network of health-system partners (over 11,000 provider locations).
- Regeneron gets the exclusive opportunity to connect Regeneron Genetics Center genomic and proteomic cohorts to TriNetX's phenotypic network; matching uses privacy-preserving methods under HIPAA and GDPR.
- Regeneron will invest up to $200 million in TriNetX as part of the collaboration.
- Stated uses: drug discovery, development and digital health.
- Not disclosed: the licence fee.
Who is involved
TriNetX is the global health research network that connects the world of drug discovery and development by sharing real-world data.
Regeneron Pharmaceuticals is an American biotechnology company.
The reading
The substrate is TriNetX's phenotypic EHR network of approximately 300 million de-identified patients; Regeneron is the party doing the enrichment, linking its RGC-generated genomic and proteomic cohorts to that phenotypic layer inside its own R&D pipeline. TriNetX provides licensed access and the federated query infrastructure, not the discovery work.
What the substrate is worth to Regeneron is its exclusive ability to anchor RGC genomic/proteomic cohorts against longitudinal phenotypes at 300-million scale (170 million in the US), feeding the buyer's own decisions about which therapeutic targets to pursue and which AI models to train for digital health products.
Licensed, de-identified access to current and future EHR data crossed to Regeneron under HIPAA/GDPR terms; the underlying hospital-identified records and the contributing HCOs' identities stayed inside the federated network per TriNetX's standard BAA structure.
Not determinable from public facts: the $200M headline bundles an equity investment with licence consideration and the announcement does not disclose how discovery outputs, downstream IP or any success-based economics are split between the parties.
Why it matters
The exclusivity is the real line item: TriNetX has agreed not to link anyone else's genomic and proteomic cohorts to its 300-million-patient phenotypic network, and Regeneron Genetics Center is the only buyer with two million sequenced exomes ready to plug in. If the licence fee was priced against access rather than against the option it extinguishes with every other drugmaker, the under-capture sits in that clause, not in the undisclosed split of the $200 million.
The argument this deal tests: The identifier on loan
Related deals
- Tempus expands multi-year Merck collaboration giving Merck access to de-identified multimodal data and Lens platform2026-03-03
- Tempus AI expands multi-year collaboration giving Gilead enterprise-wide access to Lens platform and multimodal real-world oncology data2026-04-09
- Owkin licenses K Pro AI Scientist plus multimodal oncology and immunology patient data to Boehringer Ingelheim2026-09-02
- Anthropic's $400M acquisition of Coefficient Bio for domain-specific biotech data underscores substrate dimensions2026-04-01
Sources
- markets.ft.com — primary
- prnewswire.com — corroborating
- trinetx.com — party background
- cbinsights.com — party background
- streetinsider.com — party background
- digitalhealthnews.com — party background
Announced 2026-04-02